Efficacy and Immune Activation with PEGylated human IL-10 (AM0010) in Combination with an anti-PD1 in Advanced NSCLC - Update

Deborah J. Wong1, Jeffrey G. Schneider2, Raid Aljumayl3, W. Michael Korn1, Jeffrey R. Infante4, Manish Patel4, Karen A. Autio5, Kyriakos P. Papadopoulos6, Angus Naing7, Nashat Y. Gabrail8, Pamela N. Munster9, Jonathan Goldman1, Navneet Ratti10, Peter Van Vlasselaer11, Gail L. Brown11, Annie Hung11, Martin Oth11 and Edward B. Garon11

1University of California Los Angeles (UCLA), Los Angeles, CA; 2Binghamton University Hospital, Binghamton, NY; 3OMC, Oklahoma City OK; 4University of California San Francisco (UCSF), San Francisco, CA; 5Sarah Cannon Research Institute/ Tennessee Oncology PLC, Nashville TN; 6South Cancer Research Institute/Walt Disney Cancer Specialists, Sarasota, FL; 7Memorial Sloan-Kettering Cancer Center, New York, NY; 8SARR Cancer Center, San Antonio, TX; 9ARMO BioSciences; 10Merck; 11University of Iowa Hospitals and Clinics, Iowa City, IA; **Methodological Funders of the Hansjörg Wyss Institute for Tissue Engineering and Regenerative Medicine, EPFL, Lausanne, Switzerland.

Background

AM0010 is being developed by ARMO BioSciences. AM0010 is a PEGylated human IL-10 (IL-10) that is being developed as monotherapy and in combination with an anti-PD-1 mAb, nivolumab.

Tumor antigen recognition by CD8+ T cells (TCR)

AM0010 - Mechanism of Action (Background cont.)

Results

Combination of AM0010 and anti-PD-1

• AM0010 + anti-PD-1 is well-tolerated in NSCLC
• No increase or exacerbation of autoimmune toxicities

• Recommended Phase I/II dose is 10 µg/kg, q1d in combination with an anti-PD-1

Oral - Table 1

<table>
<thead>
<tr>
<th>Treatment Combo</th>
<th>AM0010 dose (µg/kg)</th>
<th>PD-L1 %</th>
<th>DCR</th>
<th>OS-M</th>
<th>PFS-M</th>
<th>DCR (m)</th>
<th>OS (m)</th>
</tr>
</thead>
<tbody>
<tr>
<td>AM0010 + nivolumab</td>
<td>10</td>
<td>25%</td>
<td>40%</td>
<td>NR 4</td>
<td>NR 4</td>
<td>NR 4</td>
<td>NR 4</td>
</tr>
<tr>
<td>AM0010 + Pembrolizumab</td>
<td>10</td>
<td>25%</td>
<td>40%</td>
<td>NR 4</td>
<td>NR 4</td>
<td>NR 4</td>
<td>NR 4</td>
</tr>
</tbody>
</table>

Combination of AM0010 and anti-PD-1...